Currently, resveratrol is the only known GLUT1 inhibitor in the clinical trials phase for cancers such as multiple myeloma, gastrointestinal tumors, follicular lymphoma and breast cancer (Table 2). The gene discussed is SLC2A1; the disease is breast carcinoma.